v3.26.1
Interim Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
Preferred Stock [Member]
Series A-1 Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2023   $ 94,667,939 $ (97,125,921) $ (343,850) $ (2,801,832) $ 3,649,489 $ 847,657
Balance, shares at Dec. 31, 2023   118,380,930            
Net loss     (24,621,514) (24,621,514) (24,621,514)
Stock compensation expense   428,108 428,108 428,108
Equity based compensation for restricted stock unit grants   539,772 539,772 539,772
Common shares issued for services   333,333   333,333 333,333
Common shares issued for services, shares   1,500,000            
Common shares issued for earnout consideration   1,900,000 1,900,000 1,900,000
Common shares issued for earnout consideration, shares   17,491,400            
Foreign currency translation     7,314 7,314 7,314
Common shares issued for cash   1,047,533 1,047,533 $ 1,047,533
Common shares issued for cash, shares   12,635,059           35,751,969
Common shares issued for conversion of notes payable and debentures   7,083,853 7,083,853 $ 7,083,853
Common shares issued for conversion of notes payable and debentures, shares   22,395,948            
Acquisition of remaining non-controlling interest in Aya Biosciences   3,649,489 3,649,489 (3,649,489)
Common shares issued in connection with acquisition of The Leaf, LLC, shares   580,962            
Balance at Dec. 31, 2024   109,650,027 (121,747,435) (336,536) (12,433,944) (12,433,944)
Balance, shares at Dec. 31, 2024   172,984,299            
Net loss   265,776 265,776 265,776
Stock compensation expense   258,668 258,668 258,668
Equity based compensation for restricted stock unit grants   232,794 232,794 232,794
Common shares issued for services   100,000   100,000 100,000
Common shares issued for services, shares   600,000            
Common shares issued for earnout consideration   935,618 935,618 935,618
Common shares issued for earnout consideration, shares   1,858,032            
Foreign currency translation     (343) (343) (343)
Balance at Mar. 31, 2025   111,177,107 (121,481,659) (336,879) (10,641,431) (10,641,431)
Balance, shares at Mar. 31, 2025   175,442,331            
Balance at Dec. 31, 2024   109,650,027 (121,747,435) (336,536) (12,433,944) (12,433,944)
Balance, shares at Dec. 31, 2024   172,984,299            
Net loss     (17,629,675) (17,629,675) (17,629,675)
Stock compensation expense   967,579 967,579 967,579
Equity based compensation for restricted stock unit grants   1,470,020 1,470,020 1,470,020
Common shares issued for services   248,365 248,365 248,365
Common shares issued for services, shares   1,465,219            
Common shares issued for earnout consideration   935,618 935,618 935,618
Common shares issued for earnout consideration, shares   1,858,032            
Foreign currency translation   (343) (343) (343)
Common shares issued for cash   241,889 241,889 $ 241,889
Common shares issued for cash, shares   8,363,560           68,758,339
Common shares issued for trade payables   368,142 368,142 $ 368,142
Common shares issued for trade payables, shares   2,024,241            
Common shares issued for conversion of debentures and related party notes payable   17,564,048 17,564,048 17,564,048
Common shares issued for conversion of debentures and related party notes payable, shares   63,764,773            
Exercise of stock options  
Exercise of stock options, shares   302,666            
Exercise of restricted stock units  
Exercise of restricted stock units, shares   7,185,206            
Balance at Dec. 31, 2025 131,445,688 (139,377,110) (336,879) (8,268,301) (8,268,301)
Balance, shares at Dec. 31, 2025 257,947,996            
Net loss   (426,253) (426,253)
Preferred and common shares issued for cash $ 2,089,483 396,881     2,486,364
Preferred and common shares issued for cash, shares 10,726,579 8,152,200            
Shares returned to treasury (30,742)     (30,742)
Shares returned to treasury, shares (135,206)            
Stock compensation expense 6,577     6,577
Equity based compensation for restricted stock unit grants 482,890 482,890
Balance at Mar. 31, 2026 $ 2,089,483 $ 132,301,294 $ (139,803,363) $ (336,879) $ (5,749,465) $ (5,749,465)
Balance, shares at Mar. 31, 2026 10,726,579 265,964,990